KRAS
20 articles
Medicinal ChemistryJournal of Medicinal Chemistry
KRAS G12D inhibitor INCB161734: how the clinical candidate was optimized
- Optimization started from an earlier orally bioavailable KRAS G12D tool compound, with the explicit goal of lowering the predicted human dose by tuning potency and pharmacokinetics together.
- Metabolic soft-spot analysis guided the design of low-clearance analogs; molecular size and Fsp3 were held in check to improve permeability and crystalline solubility.
- The resulting candidate shows strong oral exposure, antiproliferative activity in xenograft models and selectivity over wild-type K/H/NRAS; it is now in patient trials.
Selectivity over wild-type RAS is the headline, but its origin is unclear: engagement of the mutant aspartate, as in other non-covalent G12D series, or something distinct. Keeping size and Fsp3 down while pushing clearance lower is a genuinely hard balance in this class. Cellular selectivity against G12V and G12C backgrounds would show how far the mutant preference extends.
Medicinal ChemistryACS Medicinal Chemistry Letters
Using mutant KRAS as the trigger, not just the target, for payload release
- This viewpoint proposes covalent-induced drug conjugates, where mutant KRAS is both the target and the switch that releases the drug.
- Recognition of KRAS G12C is coupled to intracellular release of potent tubulin inhibitors.
- The idea is to turn oncogene engagement into localized cytotoxicity while limiting systemic exposure to the payload.
A covalent trigger is consumed one-to-one, so payload release is capped by how much KRAS G12C a cell expresses, and approved inhibitors already compete for the same pocket. The idea lives or dies on cleavage chemistry and on whether tubulin payload leaks in normal cells; a viewpoint offers no data on either.
PharmacologyScience Translational Medicine
Mining 150,000 tumor RNA-seq datasets uncovers shared public TCRs against cancer antigens
- Statistical mining of routine clinical tumor RNA-seq from roughly 150,000 patients found recurrent, shared TCR chains linked to known cancer antigens, including HPV, mutant KRAS and CT83 presented on HLA.
- The authors developed ways to pair enriched alpha and beta chains into full receptors, then tested candidates for antigen recognition.
- Dozens of TCRs across nine peptide-HLA targets were validated, some with strong cytotoxic activity, suggesting public anticancer TCRs are common and a new source for TCR-based therapeutics.
Public TCRs are attractive because one receptor could serve many patients, but the HLA restriction still caps who qualifies. What I'd want before taking any of these forward is cross-reactivity screening against a normal-peptide panel and primary tissue, since a strong in vitro kill says little about off-target risk. Mutant KRAS and CT83 differ sharply here, and in vitro cytotoxicity won't tell you which is safer.
Medicinal ChemistryJournal of Medicinal Chemistry
Oral bis-macrocycle RMC-0708 targets active KRAS Q61H via tri-complex
- Structure-guided optimization within the tri-complex inhibitor platform produced RMC-0708, a noncovalent bis-macrocycle that engages GTP-bound KRAS Q61H.
- The compound is orally bioavailable and shows selectivity for the mutant over wild-type RAS.
- In Q61H-driven xenograft models, single oral doses gave sustained suppression of RAS pathway signaling, and dosing led to marked tumor regressions.
A noncovalent RAS(ON) inhibitor is a different game from the cysteine-trapping G12C compounds: potency has to come from the tri-complex's shape complementarity alone, with no warhead to bail you out. I'd want to see what the switch-II Q61H contact actually buys over wild-type, and whether a bis-macrocycle still leaves room to trim size and polarity for oral exposure across species.
Medicinal ChemistryJournal of Medicinal Chemistry
Zoldonrasib: an oral covalent tri-complex inhibitor of active KRAS G12D
- Structure-guided SAR optimization produced zoldonrasib, an orally available tri-complex inhibitor that selectively targets the GTP-bound, active form of KRAS G12D.
- An aziridine-2-carboxamide warhead and a rigid spirocyclic linker were key to selective covalent engagement of the mutant protein.
- The compound suppressed KRAS G12D signaling in dependent cells, showed good ADME and pharmacokinetics across species, and drove tumor regressions in xenograft models; it is now in clinical evaluation.
An aziridine on a G12D-directed ligand is a bold choice: unlike G12C cysteine chemistry, it has to find an aspartate carboxylate, so intrinsic reactivity is a selectivity risk. I'd want proteome-wide reactivity profiling and wild-type RAS occupancy data, plus GSH and plasma stability. Does the rigid spiro linker mostly pre-organize the warhead, or buy oral exposure?
Medicinal ChemistryJournal of Medicinal Chemistry
KRAS G12D inhibitor INCB161734: from oral tool compound to clinic
- Starting from an orally available tool compound, chemists tuned potency and pharmacokinetics together to lower the projected human dose.
- Mapping where the molecules were metabolized pointed to analogs with low clearance.
- Keeping size modest and raising sp3 character improved permeability and crystalline solubility.
- The result, INCB161734, offers strong oral exposure, suppresses xenograft tumor growth, spares wild-type RAS isoforms, and is now in clinical trials.
Cutting projected human dose through metabolite-ID-driven clearance fixes and higher Fsp3 is the standard playbook for a basic, polar G12D chemotype, where permeability usually sinks you. Open questions: whether the wild-type RAS sparing is real selectivity or just a cell-assay window, and how it compares with MRTX1133, which struggled to reach oral exposure.
Industry NewsIncyte / Revolution MedicinesBioSpace
Incyte's G12D Inhibitor Posts 89% Response With FOLFIRINOX in Pancreatic Cancer
- In a Phase 1 study of 54 metastatic pancreatic cancer patients, Incyte's KRAS G12D inhibitor plus mFOLFIRINOX produced an 89% confirmed response rate; with gemcitabine/nab-paclitaxel it was 69%.
- Safety was described as manageable and in line with chemotherapy alone.
- Analysts see it as competitive with Revolution Medicines' zoldonrasib (82% and 61% in comparable regimens); a first-line Phase 3 is underway.
A 7-point gap over zoldonrasib's 82% in the FOLFIRINOX setting is noise in a cross-trial comparison of a 54-patient Phase 1. The real signal is that Incyte is now a credible second contender in G12D pancreatic cancer, not a leader. With a first-line Phase 3 already running, progression-free survival and tolerability will decide the race, and this readout doesn't answer either.
Industry NewsRocheEndpoints News
Roche's divarasib cuts death risk 44% in a head-to-head against Amgen's and BMS's KRAS G12C drugs
- At ESMO 2026 Roche detailed Krascendo 1, a Phase 3 comparing its next-generation KRAS G12C inhibitor divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer.
- Divarasib reduced the risk of death by 44% versus the two marketed drugs, per Endpoints News.
- Earlier toplines had reported a progression-free survival win and no new safety signals.
A direct, randomized survival win over both approved G12C drugs is rare in oncology, where new agents usually rely on cross-trial comparisons. It gives Roche a strong claim on the second-line standard and puts pressure on Amgen and Bristol Myers Squibb, though the contest is moving to first line, where Revolution Medicines' RAS programs set the bar.
PharmacologyBritish Journal of Pharmacology (Wiley)
Review: measuring covalent inhibitor kinetics and linking them to in vivo effect
- Lead selection leans on equilibrium IC50 values, which ignore how drug and target levels shift over time; this matters most for irreversible covalent drugs.
- The review surveys assays for kinact and KI: progress curves, multi-timepoint IC50 fitting for library triage, mass spectrometry for adducts and sites, SPR/NMR, and washout experiments for reversibility and residence time.
- It then links these rates to pharmacology via protein turnover, target vulnerability and pharmacokinetics, using BTK, JAK3, KRAS G12C and EGFR cases.
On a covalent hit, an IC50 from a single timepoint says little, because potency drifts with incubation time and ranking by it can bury the compound with the best kinact/KI. Translation is the harder part: in vivo occupancy depends on how fast the target is resynthesized, so a fast-turnover protein can blunt even a well-optimized warhead. Measure turnover before trusting the kinetics.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Quinazoline-carbonitrile KRAS G12C inhibitor shows partial xenograft efficacy
- A quinazoline-6-carbonitrile series was developed as covalent KRAS G12C inhibitors for lung cancer with this mutation.
- Lead compound 8t was highly potent in a biochemical assay and in H358 NSCLC cells, suppressed ERK and AKT phosphorylation, and bound covalently and rapidly by LCMS.
- It had moderate human microsomal stability and mouse oral bioavailability, and gave partial tumor suppression in an H358 xenograft without notable weight loss.
Another acrylamide-on-switch-II chemotype, and quinazoline cores are well-trodden ground after adagrasib's tetrahydropyridopyrimidine, so novelty rests on the 6-carbonitrile. Fast covalent engagement plus pERK/pAKT knockdown is the easy part; partial H358 tumor suppression despite decent oral exposure suggests in vivo potency or residence trails sotorasib-class leads. Moderate microsomal stability is fixable, but the abstract says nothing on selectivity against other cysteine-bearing proteins.
Medicinal ChemistryACS Medicinal Chemistry Letters
Macrocyclic heteroaryl-pyrimidines target wild-type KRAS and G12D/G12V mutants
- A scaffold-hopping effort, inspired by known switch-II pocket binders, aimed to build inhibitors covering KRAS variants beyond G12C.
- Macrocyclizing a pyrazolyl-pyrimidine prototype initially gave poor in vitro activity, but the findings informed a refined design.
- The resulting lead bound KRAS G12V tightly and showed matching biochemical potency against G12V and G12D.
- Switching to isoxazolyl-pyrimidine macrocycles improved permeability and cellular activity in mutant KRAS cells.
Equal biochemical potency on G12V and G12D suggests the macrocycle grips something shared rather than mutant-specific residues, which is the intriguing part. Before I would call this a usable pan-KRAS series, though, I need wild-type data, since selectivity and on-target tolerability remain open. The isoxazole swap that rescued permeability is a practical fix, but the starting scaffold looks crowded.
Industry NewsVerastem OncologySTAT News
Verastem reports encouraging early data for its oral KRAS G12D inhibitor in pancreatic cancer
- Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others.
- Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers.
- This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.
KRAS G12D in pancreatic cancer is the biggest open space after G12C, and early activity with clean liver safety is what the field needs to see. The competitive question is durability against other G12D programs, including those from large players. Registration-directed Phase 2 trials and Fast Track status give Verastem a credible path, but single-arm early data can flatter.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
HTS-derived covalent inhibitors hit active, GTP-bound KRAS G12C
- Approved KRAS G12C drugs mostly trap the inactive GDP state and face resistance; this series targets the active GTP-bound state instead.
- A keto-indolizine HTS hit with an aniline-derived acrylamide binds Cys12 in the switch-II pocket; crystallography shows the warhead engaging the γ-phosphate of a GTP analogue.
- Optimization gave compound 17, orally bioavailable in preclinical species, which prolongs disruption of KRAS–cRAF binding and ERK signalling and produced complete regression in a pancreatic cancer xenograft.
Using the γ-phosphate to position the warhead is neat: GTP-state selectivity comes from the nucleotide itself, not only the pocket. The comparison I'd want is against RAS(ON) tri-complex inhibitors, which need cyclophilin A while this doesn't. Acrylamide reactivity and proteome-wide cysteine selectivity also matter more here than for GDP-state binders.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Isoform-selective ULK1 PROTAC gives longer autophagy suppression than an inhibitor
- ATP-competitive inhibitors struggle to separate ULK1 from the near-identical ULK2, so the authors built cereblon-recruiting degraders instead.
- Structure-guided optimization gave MR-9036, which degrades ULK1 without touching ULK2 or IMiD neo-substrates, with ternary complex formation and proteasome dependence confirmed.
- After compound washout it kept autophagy suppressed longer than the clinical ULK1/2 inhibitor DCC-3116, with antitumor activity in KRAS G12C NSCLC models.
Selectivity between paralogs is where degraders can beat occupancy-driven drugs, and this is a clean example. What I'd check next is whether ULK2 compensation shows up in vivo, and whether washout durability holds in a model with realistic drug exposure rather than a pulse.
Industry NewsMerck / SciBrunch TherapeuticsEndpoints News
Merck pays $400M upfront for SciBrunch's preclinical KRAS G12D inhibitor
- Merck took exclusive worldwide rights to SPR2015, an oral preclinical KRAS G12D (ON) inhibitor from Shanghai-based SciBrunch.
- SciBrunch gets $400M upfront, with total potential value of $2.13B across milestones.
- The deal has already closed.
$400M upfront for a preclinical asset is striking and shows how heated the KRAS G12D race has become, with China-originated assets now priced like clinical ones. For Merck it's a late entry into a field where it needs a differentiated ON-state profile, and the one to watch is first-in-human data.
PharmacologyACS Pharmacology & Translational Science (ACS)
DNA origami carrying a barnase variant is built to cleave mutant KRAS mRNA
- Mutant KRAS variants are structurally diverse and lack druggable pockets, which has limited small-molecule inhibitors.
- The authors assemble a degrader on a six-helix-bundle DNA origami scaffold that targets the mRNA rather than the protein.
- One module pairs an engineered barnase variant with a programmable recognition strand, cutting RNA directly without relying on endogenous cellular machinery; a second module is designed for cell penetration.
If KRAS has no pocket worth chasing, going after the mRNA is a fair dodge, and a catalytic barnase gives a clean mechanism: sequence-guided cleavage, no reliance on endogenous machinery. But I would want to see the data before getting excited. How well does the recognition strand discriminate single-base mutants from wild-type KRAS, given barnase's cleavage is catalytic and unforgiving of leakage? And does it survive delivery, with real potency in cells and a sensible comparison to siRNA or ASO?
Medicinal ChemistryACS Chemical Biology (ACS)
Shutting down JNK signaling resensitizes KRAS G12D-resistant pancreatic cancer cells
- Pancreatic cancer cells that adapt to KRAS G12D inhibition can be pushed back toward sensitivity by suppressing the JNK pathway more completely.
- Selective covalent inhibitors of MAP2K4, MAP2K7, or both were used to probe how much JNK suppression is needed.
- Stronger JNK blockade disables the feedback loop that reactivates KRAS signaling in resistant cells.
- Inhibitor-sensitive cells gain no benefit, so the vulnerability is specific to the resistant state.
If this holds up, the interesting part is the logic: resistance to a KRAS G12D inhibitor runs through JNK feedback, so you hit the node that rewires the pathway, not KRAS again. Covalent engagement of MAP2K4 and MAP2K7 is a neat way to ask how deep the suppression must be, though kinase selectivity between the two will be the real SAR headache. Sparing sensitive cells is the encouraging bit; it's abstract-level so far.
Industry NewsMerck / SciBrunch TherapeuticsEndpoints News
Merck Licenses China-Origin KRAS G12D Inhibitor SPR2015 for $400M Upfront
- Merck & Co. entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D molecular-glue inhibitor.
- SciBrunch will receive $400 million upfront, with total deal value up to $2.13 billion including milestone payments.
- The deal reflects a growing trend of U.S. pharma companies in-licensing China-originated oncology assets.
This plugs Merck's biggest KRAS gap: everyone's crowded into G12C, but G12D — more common in pancreatic and colorectal cancer — has stayed stubbornly undrugged with covalent chemistry. A molecular-glue approach, if it works, sidesteps that entirely. The modest 19% upfront-to-total ratio signals early-stage derisking, not a validated asset — expect Western rivals to scramble for the remaining China-origin G12D candidates.
Industry NewsHUTCHMED / GSKEndpoints News
GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B
- HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
- HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
- GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
- Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
- HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
- Initial clinical development will focus on colorectal, pancreatic and lung cancers.
Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.
Industry NewsBridgeBio Oncology TherapeuticsEndpoints News
BridgeBio Oncology Narrows BBO-8520 Focus to 2L+ NSCLC Plus Pembrolizumab
- BridgeBio Oncology Therapeutics narrowed the development scope of its lead ON/OFF-state KRAS inhibitor BBO-8520, focusing specifically on second-line-plus (2L+) NSCLC in combination with checkpoint inhibitor pembrolizumab, trimming a broader earlier-stage development plan.
- The move follows new data showing a strong objective response rate for the combination in patients whose lung cancer had already progressed on a prior KRAS G12C inhibitor, with a somewhat lower but still meaningful response rate across all doses tested.
- BBO-8520 holds FDA Fast Track designation for previously treated, KRAS G12C-mutated metastatic NSCLC.
- The company still runs two other Phase 1 KRAS-pathway programs: BBO-11818, a pan-KRAS (ON/OFF) inhibitor with Fast Track designation in pancreatic ductal adenocarcinoma, and BBO-10203, a RAS-PI3Kα interaction inhibitor enrolling the multi-tumor BREAKER-101 basket trial.
- The narrowing reads as a deliberate focusing of resources on the most differentiated combination signal, not a full retreat from the asset.
BBO-8520 sits in a brutal field — Amgen's sotorasib, Mirati/BMS's adagrasib, and Revolution Medicines' RAS(ON) inhibitors are all fishing in the same post-G12C-progression pool, so a strong response signal there is worth more to BridgeBio than thin coverage spread across earlier lines. Narrowing scope rather than killing the asset outright reads as capital discipline: in a funding environment that punishes diffuse spend, concentrating trial resources on the combination with the clearest data is the rational move, not a retreat. The two other KRAS programs (BBO-11818, BBO-10203) staying active confirms the platform bet is intact — this is portfolio triage, not a pipeline unraveling. Read the stock dip as the market's reflexive reaction to the word "narrows," not a verdict on the science; this is strategic analysis, not investment advice.